MLZ Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EDT
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€19.69M
Enterprise Value€19.89
Total Cash (Recent Filing)€9.87M
Total Debt (Recent Filing)€18.00K
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Aug 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding424,864,260
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€24.38M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA virtually debt-free capital structure and a sizable equity base materially lower refinancing and interest-rate risk, giving management time and optionality to execute restructuring, invest in commercial expansion, or pursue selective M&A while cash generation recovers.
Margin Recovery & Cost DisciplineSustained high gross margins (37%) combined with cost cuts and a return to positive adjusted EBITDA show the company can protect unit economics. Structural expense reductions and $1.0M annualized savings improve the odds of converting gross profit into durable operating profitability.
Regulatory & International PositioningPharma-grade regulatory credentials plus early commercial traction in regulated markets (France, Brazil, New Zealand, Germany) create a durable competitive advantage for API and contract manufacturing work, widening addressable markets beyond commodity adult-use demand.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business is consuming reserves to operate. Over a multi-quarter horizon this limits reinvestment, increases reliance on external funding or asset sales, and raises execution risk if revenue recovery stalls.
Revenue Decline & Top‑Line PressureMeaningful YoY revenue decline and category softness (notably adult‑use) reduce operating leverage and make fixed-cost absorption harder. Delays or seasonality in international approvals can push growth timing out and sustain top-line volatility over several quarters.
Reimbursement & Market Regulation RiskMaterial reimbursement cuts in key medical channels directly compress realized prices and margins. Structural reimbursement volatility requires longer-term product‑mix shifts or lower costs to defend profitability, raising execution and margin risk across the business.
MediPharm Labs News
MLZ FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was €0.03 and its highest was €0.05 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is €19.69M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Aug 17, 2026 which is in 10 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on May 13, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.002 by €0.002.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 424,864,260 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of €0 in its last earnings report, beating expectations of -€0.002. Following the earnings report the stock price went up 4.082%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in DE:MLZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
MLZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear near-term challenges—most notably a ~16.7% YoY revenue decline, a widened net loss and industry reimbursement headwinds—with several material positives: return to positive adjusted EBITDA, a strong 37% gross margin, meaningful operating expense reductions (‑14% YoY, ‑28% sequential), $1.0M in expected annualized savings, $9.9M cash and limited debt, and continued international commercial traction (France, New Zealand, Brazil, Germany). Management emphasizes disciplined, margin-focused execution and long-term pharma optionality supported by rare regulatory credentials. Given the company's demonstrated ability to protect margins, improve profitability metrics and maintain liquidity while advancing international expansion, the tone is cautiously optimistic.View all DE:MLZ earnings summaries